Pediatric HIV/AIDS & Infection-Related Malignancies Research Consortium for sub-Saharan Africa (PARCA)

儿童艾滋病毒/艾滋病

• 批准号: 10084671
• 负责人: CARL E ALLEN
• 金额: $ 118.51万
• 依托单位: BAYLOR COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-07-25 至 2025-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10084671
• 关键词: AIDS related cancer; AIDS/HIV problem; Acquired Immunodeficiency Syndrome; Address; Adolescent; Affect; Africa South of the Sahara; African; Biometry; Botswana; Cancer Patient; Caring; Child; Childhood; Clinical Research; Collaborations; Complement; Country; Descriptive Epidemiology; Developmental Diagnostic; Diagnosis; Education; Epidemic; Fellowship; Fellowship Program; Goals; HIV; HIV Infections; HIV diagnosis; Healthcare; Hematological Disease; Hematology; Incidence; Infrastructure; International; Kaposi Sarcoma; Laboratories; Lead; Lymphoma; Malawi; Malignant Childhood Neoplasm; Malignant Neoplasms; Modeling; Oncology; Outcome; Patient-Focused Outcomes; Patients; Pediatric Hematology; Pediatric Hospitals; Pediatric Oncologist; Pediatric Oncology; Pediatric Oncology Group; Research; Research Project Grants; Research Training; Resources; Risk; Risk Factors; Risk stratification; Site; Texas; Training; Training Programs; Translational Research; Uganda; Work; base; cancer care; cancer epidemiology; cancer survival; career development; clinical infrastructure; design; improved; improved outcome; infection related cancer; medical specialties; mortality; operation; overtreatment; patient population; pediatric human immunodeficiency virus; pediatric patients; programs; success; training opportunity

Pediatric HIV/AIDS & Infection-Related Malignancies Research Consortium for Sub-Saharan Africa (PARCA) The goal of this proposal is to establish PARCA, a collaborative clinical and translational research framework designed with the overarching goal to improve the current unacceptably poor outcomes of children with HIV- associated malignancies in sub-Saharan Africa (SSA). Currently, over 80% of children with cancer in the US survive, whereas over 80% in the majority of SSA countries die. To begin to address this disparity and improve outcomes for children with cancer in SSA, Texas Children's Hospital leveraged the clinical infrastructure of BIPAI in Uganda, Malawi, and Botswana to establish Global HOPE (Hematology-Oncology Pediatric Excellence). Global HOPE is dedicated to excellence in the care and treatment of children globally with cancer and blood disorders through state-of-the-art treatments and cutting-edge research. These three Global HOPE pediatric cancer programs, which treat patients nationwide, have begun to transform cancer care in SSA. In the US, improvements in pediatric cancer survival were achieved largely through clinical and translational research coordinated by cooperative groups such as the Children's Oncology Group. Following that model, we propose to establish a framework for collaboration to enable advances for children in SSA living with HIV and diagnosed with cancer through PARCA. The Overarching Goals of the Consortium are to: 1. Define the descriptive epidemiology and infectious exposures related to pediatric malignancies in SSA. We will determine the incidence and outcomes of HIV-associated malignancy across the BIPAI network in SSA. 2. Conduct transformative inter-disciplinary collaborative research to reduce the burden of KS and lymphoma among children and adolescents in SSA. We will establish multi-center strategies for diagnosis, risk- stratification, and outcomes improvement for children with Kaposi sarcoma and lymphoma. These studies will be best conducted in Uganda, Malawi, and Botswana, where the pediatric patient population is large enough to establish meaningful results and conclusions. Validated results will be disseminated throughout our Global HOPE network, as it continues to expand operations in SSA. 3. Support the formation of a multi-national collaborative resource in clinical and translational research, training, and career development for African scientific leaders in HIV and pediatric cancer. We will provide myriad research and training opportunities for pediatric oncologists throughout SSA to participate in and lead translational and clinical research. This program of scientific training will complement and supplement the continued success of Global HOPE Paediatric Haematology and Oncology Fellowship Program.

小儿艾滋病毒/艾滋病与感染相关的恶性肿瘤研究联盟 （PARCA） 该提案的目的是建立PARCA，这是一个合作的临床和转化研究框架 设计的总体目标是改善当前的HIV儿童的不良结果 撒哈拉以南非洲（SSA）的相关恶性肿瘤。目前，美国超过80％的癌症儿童 生存，而在大多数SSA国家中，超过80％的人死亡。开始解决这一差异并改善 德克萨斯州SSA儿童医院的癌症儿童的结果利用了 在乌干达，马拉维和博茨瓦纳建立全球希望（血液肿瘤学儿科 卓越）。全球希望致力于卓越的全球儿童护理和治疗癌症 以及通过最先进的治疗和尖端研究的血液疾病。这三个全球希望 在全国范围内治疗患者的小儿癌症计划已开始改变SSA的癌症护理。在 美国，通过临床和转化研究，在很大程度上取得了儿科癌症生存的改善 由儿童肿瘤学小组等合作团体协调。遵循该模型，我们建议 建立一个合作框架，以使SSA患有艾滋病毒和艾滋病毒和 通过PARCA诊断患有癌症。 财团的总体目标是： 1。定义与SSA儿科恶性肿瘤有关的描述性流行病学和感染性暴露。我们 将确定在SSA的Bipai网络中与HIV相关的恶性肿瘤的发生率和结果。 2。进行变革性的跨学科合作研究，以减轻KS和淋巴瘤的负担 在SSA的儿童和青少年中。我们将建立多中心策略来诊断，风险 - Kaposi肉瘤和淋巴瘤儿童的分层和结果改善。这些研究 最好在乌干达，马拉维和博茨瓦纳进行，那里的小儿患者人数很大 足以建立有意义的结果和结论。经过验证的结果将在整个过程中传播 我们的全球希望网络继续扩展SSA的运营。 3。支持在临床和转化研究中形成跨国协作资源， 非洲科学领袖艾滋病毒和小儿癌的培训和职业发展。我们将提供 SSA的小儿肿瘤学家参与和 铅翻译和临床研究。该科学培训计划将补充和补充 全球希望儿科血液学和肿瘤学研究金计划的持续成功。